1. Home
  2. IMNM vs INOD Comparison

IMNM vs INOD Comparison

Compare IMNM & INOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Immunome Inc.

IMNM

Immunome Inc.

N/A

Current Price

$18.76

Market Cap

2.5B

Sector

Health Care

ML Signal

N/A

Logo Innodata Inc.

INOD

Innodata Inc.

N/A

Current Price

$35.62

Market Cap

2.4B

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
IMNM
INOD
Founded
2006
1988
Country
United States
United States
Employees
N/A
3000
Industry
Medicinal Chemicals and Botanical Products
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
2.4B
IPO Year
2020
1996

Fundamental Metrics

Financial Performance
Metric
IMNM
INOD
Price
$18.76
$35.62
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
17
4
Target Price
$35.13
★ $111.50
AVG Volume (30 Days)
1.4M
★ 1.8M
Earning Date
11-09-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 51.40
3.37
EPS
N/A
★ 1.13
Revenue
$6,941,000.00
★ $86,775,000.00
Revenue This Year
N/A
$42.87
Revenue Next Year
N/A
$27.95
P/E Ratio
★ N/A
$32.14
Revenue Growth
N/A
★ 9.84
52 Week Low
$16.41
$34.23
52 Week High
$30.06
$125.14

Technical Indicators

Market Signals
Indicator
IMNM
INOD
Relative Strength Index (RSI) 46.46 32.21
Support Level $17.18 $34.37
Resistance Level $23.30 $47.79
Average True Range (ATR) 1.39 3.52
MACD 0.20 -0.62
Stochastic Oscillator 25.98 7.62

Price Performance

Historical Comparison
IMNM
INOD

About IMNM Immunome Inc.

Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.

About INOD Innodata Inc.

Innodata Inc is a data engineering company. It is helping companies deploy and integrate AI into their operations and products and providing AI-enabled industry platforms. The Company's operations are classified in three reporting segments: Digital Data Solutions (DDS), Synodex and Agility. Key revenue is generated from DDS segment provides AI data preparation services, collecting or creating training data, annotating training data, and training AI algorithms for its customers, and AI model deployment and integration. It also provides a range of data engineering support services including data transformation, data curation, data hygiene, data consolidation, data extraction, data compliance, and master data management.

Share on Social Networks: